Neurofibromatosis Type 1 Treatment Market in the 7MM is expected to show positive growth, and the anticipated launch of novel therapies by 2034

Neurofibromatosis Type 1 Treatment Market Size, Companies

1. KEY INSIGHTS
2. REPORT INTRODUCTION
3. EXECUTIVE SUMMARY OF NF1
4. EPIDEMIOLOGY AND MARKET METHODOLOGY
5. NF1-PN MARKET OVERVIEW AT A GLANCE
5.1. MARKET SHARE (%) DISTRIBUTION OF NF1 BY THERAPIES IN 2020 IN THE 7MM
5.2. MARKET SHARE (%) DISTRIBUTION OF NF1 BY THERAPIES IN 2034 IN THE 7MM
6. KEY EVENTS
7. DISEASE BACKGROUND AND OVERVIEW
7.1. INTRODUCTION
7.2. GENETIC MUTATIONS
7.3. CLINICAL MANIFESTATIONS
7.4. CAUSES
7.5. DIAGNOSIS
7.5.1. Differential Diagnosis
7.5.2. Diagnostic Algorithm
7.5.3. Diagnostic Guidelines
7.6. TREATMENT AND MANAGEMENT
7.6.1. Treatment Algorithm
8. EPIDEMIOLOGY AND PATIENT POPULATION
8.1. KEY FINDINGS
8.2. ASSUMPTION AND RATIONALE
8.3. TOTAL DIAGNOSED PREVALENT CASES OF NF1 IN THE 7MM
8.4. THE UNITED STATES
8.4.1. Total Diagnosed Prevalent Cases of NF1 in the United States
8.4.2. Diagnosed Prevalent Cases of NF1 Manifestations in the United States
8.4.3. Age-specific Diagnosed Prevalent Cases of NF1 in the United States
8.4.4. Severity-specific Diagnosed Prevalent Cases of cNFs in the United States
8.4.5. Age-specific Diagnosed Prevalent Cases of NF1-PN in the United States
8.4.6. NF1-PN Cases by Clinical Symptoms in the United States
8.4.7. NF1-PN Cases Eligible for Surgery in the United States
8.5. EU4 AND THE UK
8.5.1. Total Diagnosed Prevalent Cases of NF1 in EU4 and the UK
8.5.2. Diagnosed Prevalent Cases of NF1 Manifestations in EU4 and the UK
8.5.3. Age-specific Diagnosed Prevalent Cases of NF1-PN in EU4 and the UK
8.5.4. Severity-specific Diagnosed Prevalent Cases of cNFs in EU4 and the UK
8.5.5. Age-specific Diagnosed Prevalent Cases of NF1-PN in EU4 and the UK
8.5.6. NF1-PN Cases by Clinical Symptoms in EU4 and the UK
8.5.7. NF1-PN Cases Eligible for Surgery in EU4 and the UK
8.6. JAPAN
8.6.1. Total Diagnosed Prevalent Cases of NF1 in Japan
8.6.2. Diagnosed Prevalent Cases of NF1 Manifestations in Japan
8.6.3. Age-specific Diagnosed Prevalent Cases of NF1-PN in Japan
8.6.4. Severity-specific Diagnosed Prevalent Cases of cNFs in Japan
8.6.5. Age-specific Diagnosed Prevalent Cases of NF1-PN in Japan
8.6.6. NF1-PN Cases by Clinical Symptoms in Japan
8.6.7. NF1-PN Cases Eligible for Surgery in Japan
9. PATIENT JOURNEY
10. MARKETED DRUGS
10.1. KEY CROSS COMPETITION
10.2. KOSELUGO (SELUMETINIB): ASTRAZENECA AND MERCK
10.2.1. Product Description
10.2.2. Regulatory Milestones
10.2.3. Other Development Activities
10.2.4. Clinical Development
10.2.5. Safety and Efficacy
11. EMERGING DRUGS
11.1. KEY CROSS COMPETITION
11.2. MIRDAMETINIB (PD-0325901): SPRINGWORKS THERAPEUTICS
11.2.1. Product Description
11.2.2. Other Developmental Activities
11.2.3. Clinical Development
11.2.4. Safety and Efficacy
11.3. FCN-159: FOSUN PHARMACEUTICAL
11.3.1. Product Description
11.3.2. Clinical Development
11.3.3. Safety and Efficacy
11.4. HLX-1502: HEALX
11.4.1. Product Description
11.4.2. Other Developmental Activities
11.4.3. Clinical Development
11.5. NFX-179: NFlection Therapeutics
11.5.1. Product Description
11.5.2. Clinical Development
11.5.3. Safety and Efficacy
12. NF1-PN: SEVEN MAJOR MARKET ANALYSIS
12.1. KEY FINDINGS
12.2. MARKET OUTLOOK
12.3. CONJOINT ANALYSIS
12.4. KEY MARKET FORECAST ASSUMPTIONS
12.4.1 . Cost Assumptions and Rebates
12.4.2. Pricing Trends
12.4.3. Analogue Assessment
12.4.4 . Launch Year and Therapy Uptakes
12.5. TOTAL MARKET SIZE OF NF1 IN THE 7MM
12.6. THE UNITED STATES
12.6.1. Total Market Size of NF1 in the US
12.6.2. Market Size of NF1 by Therapies in the US
12.7. EU4 AND THE UK
12.7.1. Total Market Size of NF1 in the EU4 and the UK
12.7.2. Market Size of NF1 by Therapies in EU4 and the UK
12.8. JAPAN
12.8.1. Total Market Size of NF1 in Japan
12.8.2. Market Size of NF1 by Therapies in Japan
13. UNMET NEEDS
14. SWOT ANALYSIS
15. KOL VIEWS
16. MARKET ACCESS AND REIMBURSEMENT
16.1. UNITED STATES
16.1.1. Centre for Medicare and Medicaid Services (CMS)
16.2. EU4 AND THE UK
16.2.1. Germany
16.2.2. France
16.2.3. Italy
16.2.4. Spain
16.2.5. United Kingdom
16.3. JAPAN
16.3.1. MHLW
16.4. MARKET ACCESS AND REIMBURSEMENT OF NF1
17. APPENDIX
17.1. BIBLIOGRAPHY
17.2. REPORT METHODOLOGY
18. DELVEINSIGHT CAPABILITIES
19. DISCLAIMER
20. ABOUT DELVEINSIGHT

Neurofibromatosis Type 1 Market

Neurofibromatosis Type 1 Market Insight, Epidemiology And Market Forecast - 2034

Neurofibromatosis Type 1 Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Neurofibromatosis Type 1 forecasted epidemiology